200 related articles for article (PubMed ID: 34352094)
1. The susceptibility of attaining and maintaining DMARD-free remission in different (rheumatoid) arthritis phenotypes.
Luurssen-Masurel N; van Mulligen E; Weel-Koenders AEAM; Hazes JMW; de Jong PHP;
Rheumatology (Oxford); 2021 Aug; ():. PubMed ID: 34352094
[TBL] [Abstract][Full Text] [Related]
2. The number of risk factors for persistent disease determines the clinical course of early arthritis.
Luurssen-Masurel N; Weel AEAM; Koc GH; Hazes JMW; de Jong PHP;
Rheumatology (Oxford); 2021 Aug; 60(8):3617-3627. PubMed ID: 33484138
[TBL] [Abstract][Full Text] [Related]
3. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
Verstappen M; van Mulligen E; de Jong PHP; van der Helm-Van Mil AHM
RMD Open; 2020 May; 6(1):. PubMed ID: 32393523
[TBL] [Abstract][Full Text] [Related]
4. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
Verstappen M; van Steenbergen HW; de Jong PHP; van der Helm-van Mil AHM
Arthritis Res Ther; 2022 Jan; 24(1):4. PubMed ID: 34980246
[TBL] [Abstract][Full Text] [Related]
5. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Heimans L; Akdemir G; Boer KV; Goekoop-Ruiterman YP; Molenaar ET; van Groenendael JH; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Arthritis Res Ther; 2016 Jan; 18():23. PubMed ID: 26794605
[TBL] [Abstract][Full Text] [Related]
6. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
Verstappen M; Niemantsverdriet E; Matthijssen XME; le Cessie S; van der Helm-van Mil AHM
Arthritis Res Ther; 2020 Nov; 22(1):276. PubMed ID: 33228814
[TBL] [Abstract][Full Text] [Related]
7. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
8. The impact of different (rheumatoid) arthritis phenotypes on patients' lives.
Luurssen-Masurel N; Weel AEAM; Hazes JMW; de Jong PHP;
Rheumatology (Oxford); 2021 Aug; 60(8):3716-3726. PubMed ID: 33237330
[TBL] [Abstract][Full Text] [Related]
9. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
10. Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.
Wevers-de Boer KV; Heimans L; Visser K; Schouffoer AA; Molenaar ET; van Groenendael JH; Peeters AJ; Speyer I; Collée G; Huizinga TW; Allaart CF
Rheumatology (Oxford); 2015 Aug; 54(8):1380-4. PubMed ID: 25687553
[TBL] [Abstract][Full Text] [Related]
11. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
de Moel EC; Derksen VFAM; Stoeken G; Trouw LA; Bang H; Goekoop RJ; Speyer I; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2018 Feb; 20(1):33. PubMed ID: 29482627
[TBL] [Abstract][Full Text] [Related]
12. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
14. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Akdemir G; Heimans L; Bergstra SA; Goekoop RJ; van Oosterhout M; van Groenendael JHLM; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PBJ; Grillet BAM; Huizinga TWJ; Allaart CF
Ann Rheum Dis; 2018 Jan; 77(1):111-118. PubMed ID: 28970207
[TBL] [Abstract][Full Text] [Related]
15. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP
Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645
[TBL] [Abstract][Full Text] [Related]
16. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
17. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
de Moel EC; Derksen VFAM; Trouw LA; Bang H; Collée G; Lard LR; Ramiro S; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2019 Jan; 21(1):28. PubMed ID: 30658699
[TBL] [Abstract][Full Text] [Related]
18. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.
Matthijssen XME; Niemantsverdriet E; Huizinga TWJ; van der Helm-van Mil AHM
PLoS Med; 2020 Sep; 17(9):e1003296. PubMed ID: 32960885
[TBL] [Abstract][Full Text] [Related]
19. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
Boeters DM; Trouw LA; van der Helm-van Mil AHM; van Steenbergen HW
Arthritis Res Ther; 2018 May; 20(1):94. PubMed ID: 29724250
[TBL] [Abstract][Full Text] [Related]
20. Predictors of flare in rheumatoid arthritis patients with persistent clinical remission/low disease activity: Data from the TARAC cohort.
Chaiamnuay S; Jiemjit S; Songdechaphipat W; Narongroeknawin P; Pakchotanon R; Asavatanabodee P
Medicine (Baltimore); 2022 Aug; 101(32):e29974. PubMed ID: 35960097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
